American Journal of Clinical Medicine Research
ISSN (Print): 2328-4005 ISSN (Online): 2328-403X Website: Editor-in-chief: Dario Galante
Open Access
Journal Browser
American Journal of Clinical Medicine Research. 2019, 7(2), 57-59
DOI: 10.12691/ajcmr-7-2-5
Open AccessCase Report

The Association between Epileptiform Activity and Autistic Symptoms in Three Cases with Tuberous Sclerosis

Kunio Yui1, , George Imataka2, Hitomi Sasaki1 and Ryoichi Shiroki1

1Department of Urology, Fujita Health University School of Medicine, Aichi, Toyoake, 470-1192, Japan

2Department of Pediatrics, Dokkyo Medical University, Mibu 321-0293, Tochigi,Mibu, Japan

Pub. Date: October 30, 2019

Cite this paper:
Kunio Yui, George Imataka, Hitomi Sasaki and Ryoichi Shiroki. The Association between Epileptiform Activity and Autistic Symptoms in Three Cases with Tuberous Sclerosis. American Journal of Clinical Medicine Research. 2019; 7(2):57-59. doi: 10.12691/ajcmr-7-2-5


This case study examined the association between epileptic activity such as epileptiform discharges and autistic symptoms; and to examine the effect of mTOR inhibitor everolimus on seizures and epileptiform discharges in three cases with TSC and autistic symptoms. The everolimus treatment improved autistic symptoms in all four cases, however, epileptiform discharges did not disappear in all four cases with everolimus treatment. Thus, epileptiform activity and autistic symptoms may be two end-results of separate brain dysfunction. The evrolimus treatment disappeared a seizure in only one case, suggesting partial overlap between mTOR hyperactivity and a seizure in small subset of cases with TSC. This study for firstly revealed that the everolimus treatment was inefficient for epileptiform discharges. Antiepileptic therapy at early stage of brain development might be effective for epileptic activity.

tuberous sclerosis complex seizure control Epileptiform discharges autistic symptoms mTOR inhibitor

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit


[1]  Srivastava S, Sahin M. Autism spectrum disorder and epileptic encephalopathy: common causes, many questions. J Neurodev Disord. 2017, 9:23.
[2]  Feliciano DM, Lin TV, Hartman NW, Bartley CM, Kubera C, Hsieh L, et al. A circuitry and biochemical basis for tuberous sclerosis symptoms: from epilepsy to neurocognitive deficits. Int J Dev Neurosci. 2013, 31: 667-78.
[3]  Costa V, Aigner S, Vukcevic M, Sauter E, Behr K, Ebeling M, et al. mTORC1 Inhibition Corrects Neurodevelopmental and Synaptic Alterations in a Human Stem Cell Model of Tuberous Sclersis. Cell Rep. 2016, 15(1):86-95.
[4]  Wong M. mTOR as a potential treatment target for epilepsy. Future Neurol. 2012, 7:537-545.
[5]  Ryther RC, Wong M (2012) Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy. Curr Neurol Neurosci Rep. 2012, 12(4):410-8.